Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
186.72
+1.82 (+0.98%)
Streaming Delayed Price
Updated: 9:45 AM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
24,571
Open
185.99
Bid (Size)
186.63 (100)
Ask (Size)
187.29 (100)
Prev. Close
184.90
Today's Range
185.99 - 188.00
52wk Range
110.03 - 202.41
Shares Outstanding
146,800,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
↗
Today 9:29 EDT
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
↗
Today 9:18 EDT
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
+5.0%
+5.0%
1 Month
-1.2%
-1.2%
3 Month
+8.2%
+8.2%
6 Month
+25.5%
+25.5%
1 Year
+33.2%
+33.2%
More News
Read More
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
March 11, 2026
From
Biogen Inc.
Via
GlobeNewswire
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi
↗
February 08, 2026
Via
Stocktwits
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
March 10, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
March 09, 2026
Via
StockStory
Topics
Artificial Intelligence
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
March 05, 2026
From
Biogen Inc.
Via
GlobeNewswire
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
March 04, 2026
From
Biogen Inc.
Via
GlobeNewswire
3 Value Stocks Walking a Fine Line
February 18, 2026
Via
StockStory
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
February 13, 2026
Via
StockStory
Topics
Earnings
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
February 12, 2026
Via
StockStory
Biogen Announces Board Chair Transition
February 11, 2026
From
Biogen Inc.
Via
GlobeNewswire
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
February 07, 2026
Via
StockStory
Why Biogen Stock Surged Almost 9% Higher on Friday
↗
February 06, 2026
Via
The Motley Fool
What's going on in today's session: S&P500 movers
↗
February 06, 2026
Via
Chartmill
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via
MarketMinute
Topics
Intellectual Property
Biogen (BIIB) Q4 2025 Earnings Call Transcript
↗
February 06, 2026
Via
The Motley Fool
Topics
Earnings
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
February 06, 2026
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
February 06, 2026
Via
StockStory
Topics
Artificial Intelligence
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
February 04, 2026
Via
StockStory
Topics
Artificial Intelligence
World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
February 04, 2026
Via
Chartmill
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 04, 2026
From
Biogen Inc.
Via
GlobeNewswire
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
February 02, 2026
Via
StockStory
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
January 28, 2026
From
Biogen Inc.
Via
GlobeNewswire
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
↗
January 20, 2026
Via
MarketBeat
Frequently Asked Questions
Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 186.72
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 03/13/26 09:45 AM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 27.41B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 27B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.